Cargando…

Rethinking Radical Surgery in Interval Debulking Surgery for Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy

The aim of this study is to evaluate the effects on survival outcomes of the disease burden before interval debulking surgery (IDS), surgical complexity, and residual disease after IDS in advanced-stage ovarian cancer treated with neoadjuvant chemotherapy (NAC). We reviewed the data of 268 epithelia...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Yong Jae, Lee, Jung-Yun, Nam, Eun Ji, Kim, Sang Wun, Kim, Sunghoon, Kim, Young Tae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231092/
https://www.ncbi.nlm.nih.gov/pubmed/32344611
http://dx.doi.org/10.3390/jcm9041235
_version_ 1783535111029915648
author Lee, Yong Jae
Lee, Jung-Yun
Nam, Eun Ji
Kim, Sang Wun
Kim, Sunghoon
Kim, Young Tae
author_facet Lee, Yong Jae
Lee, Jung-Yun
Nam, Eun Ji
Kim, Sang Wun
Kim, Sunghoon
Kim, Young Tae
author_sort Lee, Yong Jae
collection PubMed
description The aim of this study is to evaluate the effects on survival outcomes of the disease burden before interval debulking surgery (IDS), surgical complexity, and residual disease after IDS in advanced-stage ovarian cancer treated with neoadjuvant chemotherapy (NAC). We reviewed the data of 268 epithelial ovarian cancer patients who had received three or four cycles of NAC and undergone optimal resections through IDS. The Kaplan–Meier method and Cox regression analysis were used to assess the effects of disease burden (peritoneal cancer index (PCI)), degree of complexity of surgery (surgical complexity score/s (SCS)), and extent of residual disease. In no residual disease (R0) patients, those with intermediate/high SCS had shorter progression-free survival (PFS; p = 0.001) and overall survival (OS; p = 0.001) than patients with low SCS. An analysis of a subset of patients with R0 and low PCIs showed those with intermediate/high SCS had worse PFS and OS than patients with low SCS (p = 0.049) and OS (p = 0.037). In multivariate analysis, patients with R0 as a result of intermediate/high SCS fared worse than patients whose R0 was achieved by low SCS (PFS hazard ratio (HR) 1.80, 95% CI 1.05–3.10; OS HR 5.59, 95% CI 1.70–18.39). High PCIs at the time of IDS, high SCS, and residual disease signal poor prognoses for patients treated with NAC.
format Online
Article
Text
id pubmed-7231092
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72310922020-05-22 Rethinking Radical Surgery in Interval Debulking Surgery for Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy Lee, Yong Jae Lee, Jung-Yun Nam, Eun Ji Kim, Sang Wun Kim, Sunghoon Kim, Young Tae J Clin Med Article The aim of this study is to evaluate the effects on survival outcomes of the disease burden before interval debulking surgery (IDS), surgical complexity, and residual disease after IDS in advanced-stage ovarian cancer treated with neoadjuvant chemotherapy (NAC). We reviewed the data of 268 epithelial ovarian cancer patients who had received three or four cycles of NAC and undergone optimal resections through IDS. The Kaplan–Meier method and Cox regression analysis were used to assess the effects of disease burden (peritoneal cancer index (PCI)), degree of complexity of surgery (surgical complexity score/s (SCS)), and extent of residual disease. In no residual disease (R0) patients, those with intermediate/high SCS had shorter progression-free survival (PFS; p = 0.001) and overall survival (OS; p = 0.001) than patients with low SCS. An analysis of a subset of patients with R0 and low PCIs showed those with intermediate/high SCS had worse PFS and OS than patients with low SCS (p = 0.049) and OS (p = 0.037). In multivariate analysis, patients with R0 as a result of intermediate/high SCS fared worse than patients whose R0 was achieved by low SCS (PFS hazard ratio (HR) 1.80, 95% CI 1.05–3.10; OS HR 5.59, 95% CI 1.70–18.39). High PCIs at the time of IDS, high SCS, and residual disease signal poor prognoses for patients treated with NAC. MDPI 2020-04-24 /pmc/articles/PMC7231092/ /pubmed/32344611 http://dx.doi.org/10.3390/jcm9041235 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lee, Yong Jae
Lee, Jung-Yun
Nam, Eun Ji
Kim, Sang Wun
Kim, Sunghoon
Kim, Young Tae
Rethinking Radical Surgery in Interval Debulking Surgery for Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy
title Rethinking Radical Surgery in Interval Debulking Surgery for Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy
title_full Rethinking Radical Surgery in Interval Debulking Surgery for Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy
title_fullStr Rethinking Radical Surgery in Interval Debulking Surgery for Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy
title_full_unstemmed Rethinking Radical Surgery in Interval Debulking Surgery for Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy
title_short Rethinking Radical Surgery in Interval Debulking Surgery for Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy
title_sort rethinking radical surgery in interval debulking surgery for advanced-stage ovarian cancer patients undergoing neoadjuvant chemotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231092/
https://www.ncbi.nlm.nih.gov/pubmed/32344611
http://dx.doi.org/10.3390/jcm9041235
work_keys_str_mv AT leeyongjae rethinkingradicalsurgeryinintervaldebulkingsurgeryforadvancedstageovariancancerpatientsundergoingneoadjuvantchemotherapy
AT leejungyun rethinkingradicalsurgeryinintervaldebulkingsurgeryforadvancedstageovariancancerpatientsundergoingneoadjuvantchemotherapy
AT nameunji rethinkingradicalsurgeryinintervaldebulkingsurgeryforadvancedstageovariancancerpatientsundergoingneoadjuvantchemotherapy
AT kimsangwun rethinkingradicalsurgeryinintervaldebulkingsurgeryforadvancedstageovariancancerpatientsundergoingneoadjuvantchemotherapy
AT kimsunghoon rethinkingradicalsurgeryinintervaldebulkingsurgeryforadvancedstageovariancancerpatientsundergoingneoadjuvantchemotherapy
AT kimyoungtae rethinkingradicalsurgeryinintervaldebulkingsurgeryforadvancedstageovariancancerpatientsundergoingneoadjuvantchemotherapy